AstraZeneca has entered an exclusive licence agreement with Alteogen involving the latter’s ALT-B4 platform technology.
The company plans to submit a Biologics Licence Application to the US Food and Drug Administration later in 2025 for its DMD ...
Health Canada has granted approval for Biogen’s Skyclarys to treat Friedreich’s ataxia (FA) in individuals aged 16 years and above.